In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cancer And Rare Diseases Top EU Drug Approvals In 2015

This article was originally published in Scrip

Executive Summary

  • 46 new active substances approved
  • First stem cell therapy
  • First drug for mitochondrial dysfunction
  • 12 new anticancers
  • 16 drugs for rare diseases
  • Five accelerated approvals
  • Four conditional approvals
  • Three exceptional circumstances approvals
  • Second-highest number of CHMP recommendations
  • You may also be interested in...

    

    Interpol-Led Campaign Seizes Nine Million Falsified Medical Products

    This year’s Pangea operation has led to the seizure of millions of falsified medicines and other products and the closure of 113,000 websites.

    New COVID-19 Vaccine Patent Database Launched

    As part of its drive to maximize global access to coronavirus vaccines, the Medicines Patent Pool has developed a publicly accessible resource giving information on the patent status of approved and candidate vaccines.

    More Pressure On COVID-19 Product Protections As Euro Parliament Backs IP Waiver

    Expectations will be high after the COVID-19 product IP waiver plan took a big step forward and G7 leaders prepare for discussions on the global recovery from coronavirus, tackling climate change and other weighty subjects.

    Topics

    UsernamePublicRestriction

    Register

    SC064222

    Ask The Analyst

    Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

    Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

    All fields are required.

    Please make sure all fields are completed.

    Please make sure you have filled out all fields

    Please make sure you have filled out all fields

    Please enter a valid e-mail address

    Please enter a valid Phone Number

    Ask your question to our analysts

    Cancel